HIV Antiretroviral Therapy


Article Author:
Tyler Kemnic


Article Editor:
Peter Gulick


Editors In Chief:
Lauren Camaione


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
9/6/2019 9:58:19 PM

Indications

The first therapy to work against HIV was the nucleoside reverse transcriptase inhibitor zidovudine. The FDA approved this in 1987. By 1996, research showed the advantages of combining medicines to treat HIV. Using HIV medicines for treatment is called antiretroviral therapy (ART). This form of treatment is recommended for all patients with HIV by the Department of Health and Human Services (DHHS) and the World Health Organization (WHO). This daily treatment of multiple HIV medications is an HIV regimen. A typical, initial HIV regimen includes three HIV medications from a minimum of two drug classes. Although this treatment is not curative, it can provide longer lives for patients and reduce HIV transmission. This reduction of transmission has become a popular use of antiretroviral therapy for individuals who are HIV-positive and are with an HIV-negative partner. The successes of antiretroviral therapy have reduced HIV to a chronic condition in many parts of the world as progression to AIDS has become rare. Studies have found that 3-drug therapy has led to a 60% to 80% decline in rates of AIDs, hospitalization, and death. By 2030 the CDC plans to implement a 90-90-90 plan (90% HIV diagnosed, 90% on therapy, and 90% suppressed). 

The goal of HIV medicines is to prevent HIV from multiplying. There are six classes of drugs used in antiretroviral therapy. These drugs generally fall into classes according to the phase of the HIV life cycle inhibited by them. More common combinations include two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or integrase inhibitor (II). The drugs are listed below according to their class and generic names.

People who are exposed to HIV-positive infectious bodily fluids either by skin puncture, damaged skin, or direct mucous membrane contact are at risk for transmission and should start antiretroviral therapy as soon as possible. The United States Public Health Service guidelines recommend starting prophylactics up to 72 hours post-exposure. The recommended regimen is emtricitabine plus tenofovir plus raltegravir for four weeks. Those who get exposed to HIV should have follow-up HIV testing at 6, 12, and 24 weeks. If the test results are negative at 24 weeks, they are considered uninfectious.[1]

A recent HIV Infection is one that occurs up to 6 months after infection. An HIV regimen often varies based on potential drug interactions with the patient's current medications and the adverse effects experienced.

Patients who are pregnant should begin treatment immediately to prevent mother-to-child transmission of HIV and protect the health of the woman.[2][3][4][5][6]

The following includes all FDA-approved HIV medications:

  • NRTIs: Abacavir, emtricitabine, lamivudine; Tenofovir disoproxil fumarate, zidovudine
  • NNRTIs: Efavirenz, etravirine, nevirapine, rilpivirine
  • Fusion inhibitors (FIs): Enfuvirtide
  • Protease inhibitors (PIs): Atazanavir, darunavir, fosamprenavir, ritonavir, saquinavir, tipranavir
  • CCR5 Antagonist: Maraviroc
  • IIs: Dolutegavir, raltegravir, elvitegravir, bictegravir
  • Post-Attachment Inhibitors: Ibalizumab
  • Pharmacokinetic Enhancers: Cobicistat

The following includes all FDA-approved HIV combination medicines:

  • Abacavir and lamivudine
  • Abacavir, dolutegravir, and lamivudine
  • Abacavir, lamivudine, and zidovudine
  • Atazanavir and cobicistat
  • Bictegravir, emtricitabine, and tenofovir alafenamide
  • Darunavir and cobicistat
  • Dolutegravir and rilpivirine
  • Efavirenz, emtricitabine, and tenofovir disoproxil fumarate
  • Efavirenz, lamivudine, and tenofovir disoproxil fumarate
  • Efavirenz, lamivudine, and tenofovir disoproxil fumarate
  • Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate
  • Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
  • Emtricitabine, rilpivirine, and tenofovir alafenamide
  • Emtricitabine, rilpivirine, and tenofovir disoproxil fumarate
  • Emtricitabine and tenofovir alafenamide
  • Emtricitabine and tenofovir disoproxil fumarate
  • Lamivudine and tenofovir disoproxil fumarate
  • Lamivudine and zidovudine
  • Lopinavir and ritonavir

The FDA does not approve investigational HIV drugs. Investigational drugs include those used to treat or prevent HIV and vaccines to treat or prevent HIV. These drugs are only available in clinical trials. No vaccines exist yet; however, researchers are studying this possibility.[7]

Mechanism of Action

NRTIs

Compete with natural deoxynucleotides for incorporation into a growing viral DNA chain. However, NRTIs lack a 3'-hydroxyl group on the deoxyribose moiety. This difference results in incorporation of an NRTI, and the next incoming deoxynucleotide cannot form the following 5', 3' phosphodiester bond needed to extend the DNA chain. The result is a chain termination in DNA synthesis.

NNRTIs

Block reverse transcriptase (RT) by directly binding to the enzyme. Though NNRTIs do not get incorporated into the viral DNA, they inhibit movement of protein domains of RT that are essential to carry out the DNA synthesis.

Protease Inhibitors

Bind HIV-1 protease and block proteolytic cleavage of protein precursors that are necessary for the production of viral particles.

Fusion Inhibitors

Disrupt binding, fusion, and entry of HIV virions into a human cell. Enfuvirtide binds to gp41 and disrupts membrane attachment.

CCR5 Antagonist

Maraviroc blocks the CCCR receptor on the T-Cell to prevent viral attachment.

Integrase Inhibitors

Block the action of integrase, preventing the viral genome from inserting itself into the DNA of a host cell.

Post-Attachment Inhibitors

This class is a monoclonal antibody that binds CD4 inhibiting viral entry into the cell.

Pharmacokinetic Enhancers

Inhibition of human CYP3A protein, increasing plasma concentration of other anti-HIV drugs.

Administration

The standard of care in an HIV regimen is to prevent HIV mutation. As a patient will take these medications orally, there are now several options that combine three to four drugs into one pill for once-daily administration. This dosing increases both adherence and long-term effectiveness. Ibalizumab is an exception as it is an injectable agent.[8]

Patients are tested and educated to take all of their medications correctly to reduce resistance and cross-resistance to similar drugs to those they are taking. Medication adherence has been found to be difficult due to adverse effects following an HIV regimen. Common barriers to adherence include trouble swallowing pills, busy schedule (shift work), unstable living/housing situations, alcohol and drug use, fear of disclosing HIV status, and lack of insurance. Before starting an HIV regimen, strategies such as 7-day pillboxes and/or phone applications and alarms should be in place. Patients must have stable mental health and not be taking illicit drugs to have better adherence.[9][10]

Adverse Effects

NRTIs

Hypersensitivity reaction or rash, neutropenia, myopathy, anemia, neuropathy, mitochondrial toxicity, lactic acid build-up, pancreatitis, fever, rash, nausea, vomiting, diarrhea, abdominal pain, fatigue, achiness, shortness of breath, sore throat, dark-colored urine, lipoatrophy, and jaundice[11]

NNRTIs

Severe rash, allergic reactions, depression, impaired concentration, headache, sleep disturbance, abnormal dreams, mood changes, jaundice, dark-colored urine, fatigue, nausea and vomiting, peripheral neuropathy, mouth sores, conjunctivitis, myopathy, blisters, and trouble breathing

Protease Inhibitors

Irregular heart rhythm, lipohypertrophy, severe rash, jaundice, dizziness, lightheadedness, heartburn, fatigue, myopathy, conjunctivitis, mouth sores, mouth numbness, kidney stones, blisters, dark-colored urine, pancreatitis, painful swelling, and abdominal pain

Fusion Inhibitors

Injection site reactions, infection, trouble breathing, fever, blood in urine, dark- colored urine, low blood pressure, neutropenia, chills and shivering, and cough

CCR5 Antagonist

Allergic reaction, jaundice, dark-colored urine, vomiting, abdominal pain, fever, fatigue, myopathy, mouth and skin blisters, facial swelling, trouble breathing, upper respiratory tract infections, cough, joint pain, myopathy, pain below ribs, heart problems, and loss of appetite

Integrase Inhibitors

Allergic hypersensitivity reaction, rash, jaundice, dark-colored urine, pale bowel movements, diarrhea, flatulence, nausea and vomiting, loss of appetite, abnormal dreams, pruritus, pain below ribs, mouth and skin blisters, and fatigue

Post-Attachment Inhibitors

Immune reconstitution inflammatory syndrome

Pharmacokinetic Enhancers

Increased serum creatinine, proteinuria, nausea, diarrhea, headache, and acute kidney injury and kidney failure 

Some long-term adverse effects that may occur from HIV medicines are hepatotoxicity, kidney failure, heart disease, diabetes/insulin resistance, hyperlipidemia, osteoporosis, suicidal ideation/depression, and nervous system deficits.[12][13]

Contraindications

Abacavir: Patients who have the HLA-B*5701 allele, or with a prior hypersensitivity reaction to abacavir or with moderate or severe hepatic impairment.[14]

Emtricitabine: Patients with previously demonstrated hypersensitivity to any of the components of the products.

Lamivudine: Patients with a previous hypersensitivity reaction to lamivudine.

Tenofovir Disoproxil Fumarate: Previous hypersensitivity and/or glomerular filtration rate (GFR) less than 50.

Zidovudine: Patients who have had potentially life-threatening allergic reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) to any of the components of the formulations.

Efavirenz: Patients with clinically significant hypersensitivity, for example, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the ingredients of this product. Coadministration of efavirenz with elbasvir and grazoprevir is contraindicated.

Etravirine: Hypersensitivity

Nevirapine: In patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment or for use as occupational and non-occupational post-exposure prophylaxis (PEP) regimens. Women with CD4 greater than 250 or men with CD4 greater than 400 due to an increased probability of hypersensitivity reaction. 

Rilpivirine: Contraindicated for co-administration with all of the following; carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, dexamethasone, St. John’s wort, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole.

Atazanavir: In patients with previously demonstrated clinically significant hypersensitivity, for example, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions, to any of the ingredients of formulations. When co-administered with medications that are highly dependent on CYP3A or UGT1A1 for clearance, and for patients in which elevated plasma concentrations of the interacting drugs are associated with serious and life-threatening events. When co-administered with drugs that strongly induce CYP3A4 it may lead to lower exposure and loss of efficacy of formulations.

Darunavir: Co-administration of formulations is contraindicated with medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and life-threatening events.

Fosamprenavir: In patients with previously demonstrated clinically significant hypersensitivity, for example, Stevens-Johnson syndrome, to any of the components of this product or amprenavir. When co-administered with medications that are highly dependent on cytochrome P450 3A4 (CYP3A4) for clearance and for which elevated plasma concentrations are associated with serious and life-threatening events.

Ritonavir: Contraindicated in patients with known hypersensitivity, for example, toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome, to ritonavir or any of its ingredients. Ritonavir is contraindicated with medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and life-threatening reactions. It is also contraindicated with medications that are potent CYP3A inducers, where significantly reduced lopinavir plasma concentrations may correlate with the potential for loss of virologic response and possible resistance and cross-resistance.[15]

Saquinavir: Contraindicated in those with congenital long QT syndrome, those with refractory hypokalemia or hypomagnesemia, and combination with drugs that both increase saquinavir plasma concentrations and prolong the QT interval. Is also contraindicated in people with complete atrioventricular (AV) block without implanted pacemakers, or in patients who are at high risk of complete AV block. Contraindicated in patients with clinically significant hypersensitivity (e.g., anaphylactic reaction, Stevens-Johnson syndrome) to saquinavir, saquinavir mesylate, or any of its ingredients. Contraindicated in patients with severe hepatic impairment. Is also contraindicated with drugs that are CYP3A substrates for which increased plasma levels may result in serious or life-threatening reactions.

Tipranavir: Contraindicated in moderate to severe hepatic impairment and co-administration with drugs that are highly dependent on CYP 3A for clearance or are potent CYP 3A inducers. Increased risk of intracranial bleeding.

Enfuvirtide: Known hypersensitivity to enfuvirtide or any of its components.

Maraviroc: This drug is contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers.

Dolutegravir: With previous hypersensitivity reaction to dolutegravir or receiving dofetilide due to the potential for higher dofetilide plasma concentrations and the risk for serious and life-threatening events.

Raltegravir: None

Ibalizumab: None

Cobicistat: The concomitant use of cobicistat with atazanavir or darunavir and is contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect.

Monitoring

Initial Assessment/Start of Antiretroviral Therapy

  • CD4 Count
  • HIV viral load
  • Resistance testing
  • HLA-B 5701 testing
  • Tropism testing
  • Hepatitis B serology
  • Hepatitis C screening
  • Complete blood count (CBC) with differential
  • Basic chemistry 
  • ASL/AST/bilirubin
  • Fasting lipid profile
  • Fasting glucose and hemoglobin A1C
  • Urinalysis
  • Pregnancy Test 

Every 3 to 6 Months

  • CD4 count for first 2 years of antiretroviral therapy or if viremia develops
  • HIV viral load
  • Basic chemistry
  • ALT/AST/ bilirubin
  • CBC with differential if on zidovudine
  • Fasting glucose and hemoglobin A1C if abnormal before

Every 6 Months

  • CBC with differential
  • Urinalysis if on (bictegravir, emtricitabine, and tenofovir alafenamide) or (efavirenz, emtricitabine, and tenofovir disoproxil fumarate

Every 12 Months

  • After two years, if the CD4 count is 300 to 500, then every 12 months; if CD4 is greater than 500, monitoring is optional
  • Hepatitis B serology may be repeated unless immunized
  • Hepatitis C screen if the patient is at risk
  • Fasting lipid profile
  • Fasting glucose and hemoglobin A1C
  • Urinalysis
  • Quantiferon TB test

Treatment Failure/Modification

  • CD4 count
  • HIV viral load
  • Resistance testing
  • Tropism testing
  • Hepatitis B serology
  • Hepatitis C screening
  • Basic chemistry
  • ALT/AST/bilirubin
  • CBC with differential
  • Fasting lipid profile
  • Fasting glucose and hemoglobin A1C
  • Urinalysis
  • Pregnancy test

Toxicity

Many HIV medicines have adverse effects that may require supportive treatment, monitoring, and adjustment of the HIV regimen.[12]

Enhancing Healthcare Team Outcomes

The management of HIV patients is best done with a multidisciplinary team that also includes the pharmacist and infectious disease nurse. The pharmacist should verify the chosen regimen, check for drug interactions, verify dosing, and assumes a responsibility for patient counseling. Nursing can make an initial assessment on treatment effectiveness and especially patient compliance. Nursing also must participate in patient education, because improer complaince can lead to disastrous therapeutic failure. All members of the healthcare team must press the point of compliance when they have the opportunity, and any concerns about the regimen or compliance must be communicated to the treating physician.

There is overwhelming data showing that HAART can improve survival and reduce the risk of opportunistic infections. Thus, healthcare workers need to understand these medications not only because of their effectiveness but also the potential adverse effects that can occur. When in doubt about HAART, a consultation with an infectious disease expert is recommended.

Only with a complete "all in", collaborative interprofessional team approach can ART have its best chance for therapeutic success while minimizing adverse events. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

HIV Antiretroviral Therapy - Questions

Take a quiz of the questions on this article.

Take Quiz
In a patient is diagnosed with HIV, at what CD4 count should they be treated with antiretroviral therapy?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient has a new diagnosis of HIV. What is the most important factor in determining when to start antiretroviral therapy (ART)?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with HIV/AIDS is being treated with nelfinavir, lamivudine, and zidovudine. His only side effect is fatigue. The viral load is suppressed, but a complete blood count shows WBC 5,000 cells/mm3, Hgb 10.3 g/dL, Hct 30.2%, Plts 132,000 cells/mm3, and MCV 109 fL. Which of the following statements is true?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with HIV/AIDS has been maintained on nelfinavir plus lamivudine and zidovudine for six months. At four months, there was no detectable viral RNA. He reports a 15-pound weight loss, night sweats, but no fevers. Labs show WBC 3,600 cells/mm3, Hgb 9.6 g/dL, Plts 140,000, and MCV 113 fL. Viral load is 8,000 copies/ml and the CD4+ count has decreased. Which of the following is the appropriate treatment for this patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with HIV is started on Indinavir (Crixivan), Stavudine (d4T), and Didanosine (ddI). The patient develops severe right flank pain with radiation to the groin. The patient has urgency, dark urine, and hesitance. On exam, the patient is in severe pain, with right upper quadrant tenderness to deep palpation and right costovertebral angle (CVA) tenderness. Which of the following choices is appropriate for the management of this patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A newborn infant is diagnosed with HIV and started on highly active antiretroviral therapy (HAART). The infant is evaluated, and the mother admits she stopped the medication two months ago because she kept missing doses. Laboratory results show a CD4+ count of 300 cells/mm3 and an HIV viral load of 50,000 copies/mL. Previously the CD4+ count was 700 cells/mm3, and the HIV viral load was 6,000 copies/mL. Which of the following is appropriate for the management of this infant?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What advice should be given to an adult male who is HIV positive with a CD4 count of 190 and a viral load of 200,000 copies per mL and has no evidence of opportunistic infection?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which one of the following HIV medications may cause strange dreams and night terrors?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following antiretroviral medication is not recommended for use in infants?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old woman comes to your office to establish primary care. She has not been seen by a doctor in 15 years and says she has been very healthy and endorses no complaints. Family history is only positive for breast cancer in a maternal aunt. On social history she says she is has been married for 3 years and is in a monogamous relationship, they use condoms intermittently, although admits that in the past she had multiple sexual partners. Routine testing reveals positive for HIV-1. Further testing shows a CD4 count of 1075. What should the next step be?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient is newly diagnosed with HIV and is to begin ART, which of the following combinations is the most common for an HIV regime?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
When is antiretroviral therapy (ART) initiation is recommended?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

HIV Antiretroviral Therapy - References

References

Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults., Badii VS,Buabeng KO,Agyarko Poku T,Forkuo AD,Boamah BB,Arhin SM,Kpewou DE,, International journal of chronic diseases, 2018     [PubMed]
Use of antiretroviral therapy during pregnancy and adverse birth outcomes among women living with HIV-1 in low and middle-income countries: a systematic review., Saleska JL,Turner AN,Maierhofer C,Clark J,Kwiek JJ,, Journal of acquired immune deficiency syndromes (1999), 2018 May 25     [PubMed]
Mother-to-child transmission of HIV in Australia and other high-income countries: Trends in perinatal exposure, demography and uptake of prevention strategies., O'Donovan K,Emeto TI,, The Australian & New Zealand journal of obstetrics & gynaecology, 2018 May 22     [PubMed]
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1., Negredo E,Clotet B,, Expert opinion on pharmacotherapy, 2018 May 16     [PubMed]
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population., Chawla A,Wang C,Patton C,Murray M,Punekar Y,de Ruiter A,Steinhart C,, Infectious diseases and therapy, 2018 May 14     [PubMed]
Adherence to Highly Active Antiretroviral Therapy Among Children in Ethiopia: A Systematic Review and Meta-analysis., Endalamaw A,Tezera N,Eshetie S,Ambachew S,Habtewold TD,, AIDS and behavior, 2018 May 14     [PubMed]
Ibalizumab., Bettiker RL,Koren DE,Jacobson JM,, Current opinion in HIV and AIDS, 2018 Jul     [PubMed]
Barriers to antiretroviral therapy adherence in developed countries: a qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure., Engler K,Lènàrt A,Lessard D,Toupin I,Lebouché B,, AIDS care, 2018 May 2     [PubMed]
HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data., Tarasova O,Poroikov V,, Molecules (Basel, Switzerland), 2018 Apr 19     [PubMed]
HIV Vaccination: A Roadmap among Advancements and Concerns., Trovato M,D'Apice L,Prisco A,De Berardinis P,, International journal of molecular sciences, 2018 Apr 19     [PubMed]
Abacavir Therapy and <i>HLA-B*57:01</i> Genotype, Dean L,,, 2012     [PubMed]
HIV Lipoatrophy, Bhimji SS,Whitten RA,,, 2018 Jan     [PubMed]
HIV Preexposure Prophylaxis: A Review., Riddell J 4th,Amico KR,Mayer KH,, JAMA, 2018 Mar 27     [PubMed]
Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update., Zanetti HR,Roever L,Gonçalves A,Resende ES,, Current atherosclerosis reports, 2018 Feb 8     [PubMed]
Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?, Burgos J,Ribera E,Falcó V,, AIDS reviews, 2018 Jan-Mar     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pharmacy-Pediatric. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pharmacy-Pediatric, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pharmacy-Pediatric, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pharmacy-Pediatric. When it is time for the Pharmacy-Pediatric board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pharmacy-Pediatric.